# Lexicon Pharmaceuticals, Inc.: financial statements, quarterly

LXRX · Nasdaq · CIK 1062822 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lxrx.md) · [Financials](/companies/lxrx/financials.md) · [Filings](/companies/lxrx/filings.md) · [Insiders](/companies/lxrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lxrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001062822-24-000060.md) | [0.7 d](/filings/0001062822-25-000013.md) | [1.1](/filings/0001062822-25-000029.md) | [1.6](/filings/0001062822-24-000046.md) | [1.7](/filings/0001062822-24-000060.md) | [1.6 d](/filings/0001062822-25-000013.md) | [1.3](/filings/0001062822-25-000029.md) | [28.9](/filings/0001062822-26-000117.md) | [14.2](/filings/0001062822-25-000054.md) | [5.5 d](/filings/0001062822-26-000050.md) | [21.1](/filings/0001062822-26-000101.md) | [0.7](/filings/0001062822-26-000117.md) |
| Cost of revenue | $m | [0.0](/filings/0001062822-24-000060.md) | [0.1 d](/filings/0001062822-26-000050.md) | [0.0](/filings/0001062822-25-000029.md) | [0.2](/filings/0001628280-25-038340.md) | [0.1](/filings/0001062822-25-000054.md) | [0.3 d](/filings/0001062822-26-000050.md) | [0.0](/filings/0001062822-26-000101.md) | [0.0](/filings/0001062822-26-000117.md) | [0.0](/filings/0001062822-25-000054.md) | [0.2 d](/filings/0001062822-26-000050.md) | [0.1](/filings/0001062822-26-000101.md) | [0.0](/filings/0001062822-26-000117.md) |
| Research and development | $m | [17.6](/filings/0001062822-24-000060.md) | [14.8 d](/filings/0001062822-26-000050.md) | [14.4](/filings/0001062822-25-000029.md) | [17.6](/filings/0001628280-25-038340.md) | [25.8](/filings/0001062822-25-000054.md) | [26.7 d](/filings/0001062822-26-000050.md) | [15.3](/filings/0001062822-26-000101.md) | [15.7](/filings/0001062822-26-000117.md) | [18.8](/filings/0001062822-25-000054.md) | [11.3 d](/filings/0001062822-26-000050.md) | [12.8](/filings/0001062822-26-000101.md) | [17.4](/filings/0001062822-26-000117.md) |
| Selling, general and administrative | $m | [32.2](/filings/0001062822-24-000060.md) | [32.6 d](/filings/0001062822-26-000050.md) | [32.1](/filings/0001062822-25-000029.md) | [39.2](/filings/0001628280-25-038340.md) | [39.6](/filings/0001062822-25-000054.md) | [32.3 d](/filings/0001062822-26-000050.md) | [11.6](/filings/0001062822-26-000101.md) | [9.4](/filings/0001062822-26-000117.md) | [7.6](/filings/0001062822-25-000054.md) | [8.8 d](/filings/0001062822-26-000050.md) | [9.2](/filings/0001062822-26-000101.md) | [9.8](/filings/0001062822-26-000117.md) |
| Operating income | $m | [(49.6)](/filings/0001062822-24-000060.md) | [(46.7) d](/filings/0001062822-26-000050.md) | [(45.3)](/filings/0001062822-25-000029.md) | [(55.4)](/filings/0001628280-25-038340.md) | [(63.7)](/filings/0001062822-25-000054.md) | [(32.7) d](/filings/0001062822-26-000050.md) | [(25.7)](/filings/0001062822-26-000101.md) | [3.7](/filings/0001062822-26-000117.md) | [(12.2)](/filings/0001062822-25-000054.md) | [(14.8) d](/filings/0001062822-26-000050.md) | [(1.0)](/filings/0001062822-26-000101.md) | [(26.5)](/filings/0001062822-26-000117.md) |
| Interest expense | $m | [3.9](/filings/0001062822-23-000058.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(50.5)](/filings/0001062822-24-000060.md) | [(49.8) d](/filings/0001062822-26-000050.md) | [(48.4)](/filings/0001062822-25-000054.md) | [(53.4)](/filings/0001062822-25-000054.md) | [(64.8)](/filings/0001062822-25-000054.md) | [(33.8) d](/filings/0001062822-26-000050.md) | [(25.3)](/filings/0001062822-26-000117.md) | [3.3](/filings/0001062822-26-000117.md) | [(12.8)](/filings/0001062822-25-000054.md) | [(15.5) d](/filings/0001062822-26-000050.md) | [(1.0)](/filings/0001062822-26-000117.md) | [(31.8)](/filings/0001062822-26-000117.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001062822-24-000060.md) | not reported | [(0.20)](/filings/0001062822-25-000029.md) | [(0.17)](/filings/0001628280-25-038340.md) | [(0.18)](/filings/0001062822-25-000054.md) | not reported | [(0.07)](/filings/0001062822-26-000101.md) | [0.01](/filings/0001062822-26-000117.md) | [(0.04)](/filings/0001062822-25-000054.md) | not reported | [0.00](/filings/0001062822-26-000101.md) | [(0.07)](/filings/0001062822-26-000117.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001062822-24-000060.md) | not reported | [(0.20)](/filings/0001062822-25-000029.md) | [(0.17)](/filings/0001628280-25-038340.md) | [(0.18)](/filings/0001062822-25-000054.md) | not reported | [(0.07)](/filings/0001062822-26-000101.md) | [0.01](/filings/0001062822-26-000117.md) | [(0.04)](/filings/0001062822-25-000054.md) | not reported | [0.00](/filings/0001062822-26-000101.md) | [(0.07)](/filings/0001062822-26-000117.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.1](/filings/0001062822-23-000058.md) | [22.5](/filings/0001062822-25-000013.md) | [96.5](/filings/0001062822-24-000024.md) | [35.6](/filings/0001062822-24-000046.md) | [34.6](/filings/0001062822-24-000060.md) | [66.7](/filings/0001062822-26-000050.md) | [62.9](/filings/0001062822-25-000029.md) | [21.4](/filings/0001628280-25-038340.md) | [49.7](/filings/0001062822-25-000054.md) | [34.3](/filings/0001062822-26-000117.md) | [38.1](/filings/0001062822-26-000101.md) | [40.9](/filings/0001062822-26-000117.md) |
| Current assets | $m | [223](/filings/0001062822-23-000058.md) | [177](/filings/0001062822-25-000013.md) | [365](/filings/0001062822-24-000024.md) | [321](/filings/0001062822-24-000046.md) | [269](/filings/0001062822-24-000060.md) | [246](/filings/0001062822-26-000050.md) | [246](/filings/0001062822-25-000029.md) | [145](/filings/0001628280-25-038340.md) | [123](/filings/0001062822-25-000054.md) | [102](/filings/0001062822-26-000117.md) | [186](/filings/0001062822-26-000101.md) | [197](/filings/0001062822-26-000117.md) |
| Total assets | $m | [276](/filings/0001062822-23-000058.md) | [229](/filings/0001062822-25-000013.md) | [417](/filings/0001062822-24-000024.md) | [373](/filings/0001062822-24-000046.md) | [321](/filings/0001062822-24-000060.md) | [298](/filings/0001062822-26-000050.md) | [298](/filings/0001062822-25-000029.md) | [226](/filings/0001628280-25-038340.md) | [206](/filings/0001062822-25-000054.md) | [185](/filings/0001062822-26-000117.md) | [269](/filings/0001062822-26-000101.md) | [250](/filings/0001062822-26-000117.md) |
| Current liabilities | $m | [32.3](/filings/0001062822-23-000058.md) | [31.5](/filings/0001062822-25-000013.md) | [23.4](/filings/0001062822-24-000024.md) | [27.9](/filings/0001062822-24-000046.md) | [36.0](/filings/0001062822-24-000060.md) | [45.2](/filings/0001062822-26-000050.md) | [111](/filings/0001062822-25-000029.md) | [34.8](/filings/0001628280-25-038340.md) | [21.7](/filings/0001062822-25-000054.md) | [20.9](/filings/0001062822-26-000117.md) | [9.9](/filings/0001062822-26-000101.md) | [14.7](/filings/0001062822-26-000117.md) |
| Total liabilities | $m | [137](/filings/0001062822-23-000058.md) | [136](/filings/0001062822-25-000013.md) | [128](/filings/0001062822-24-000024.md) | [133](/filings/0001062822-24-000046.md) | [143](/filings/0001062822-24-000060.md) | [152](/filings/0001062822-26-000050.md) | [175](/filings/0001062822-25-000029.md) | [96.1](/filings/0001628280-25-038340.md) | [85.8](/filings/0001062822-25-000054.md) | [77.4](/filings/0001062822-26-000117.md) | [66.0](/filings/0001062822-26-000101.md) | [75.5](/filings/0001062822-26-000117.md) |
| Long-term debt | $m | [99.3](/filings/0001062822-23-000058.md) | [99.5](/filings/0001062822-25-000013.md) | [99.9](/filings/0001062822-24-000024.md) | [99.5](/filings/0001062822-24-000046.md) | [99.9](/filings/0001062822-24-000060.md) | [100](/filings/0001062822-26-000050.md) | [58.6](/filings/0001062822-25-000029.md) | [56.1](/filings/0001628280-25-038340.md) | [56.5](/filings/0001062822-25-000054.md) | [49.4](/filings/0001062822-26-000117.md) | [49.7](/filings/0001062822-26-000101.md) | [51.4](/filings/0001062822-26-000117.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001062822-26-000050.md) | [42.1](/filings/0001062822-25-000029.md) | not reported | not reported | [4.6](/filings/0001062822-26-000117.md) | [0.0](/filings/0001062822-26-000101.md) | [0.0](/filings/0001062822-26-000117.md) |
| Shareholders' equity | $m | [140](/filings/0001062822-23-000058.md) | [93.1](/filings/0001062822-25-000013.md) | [289](/filings/0001062822-24-000024.md) | [240](/filings/0001062822-24-000046.md) | [179](/filings/0001062822-24-000060.md) | [146](/filings/0001062822-26-000050.md) | [123](/filings/0001062822-25-000029.md) | [129](/filings/0001628280-25-038340.md) | [120](/filings/0001062822-25-000054.md) | [108](/filings/0001062822-26-000117.md) | [203](/filings/0001062822-26-000101.md) | [175](/filings/0001062822-26-000117.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(41.6) d](/filings/0001062822-24-000060.md) | [(50.5) d](/filings/0001062822-26-000050.md) | [(55.1)](/filings/0001062822-25-000029.md) | [(48.5) d](/filings/0001628280-25-038340.md) | [(53.6) d](/filings/0001062822-25-000054.md) | [(21.5) d](/filings/0001062822-26-000050.md) | [(43.8)](/filings/0001062822-26-000101.md) | [17.0 d](/filings/0001062822-26-000117.md) | [(23.8) d](/filings/0001062822-25-000054.md) | [(17.2) d](/filings/0001062822-26-000050.md) | [(14.7)](/filings/0001062822-26-000101.md) | [(9.2) d](/filings/0001062822-26-000117.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001062822-24-000060.md) | [0.0 d](/filings/0001062822-26-000050.md) | [0.0](/filings/0001062822-24-000024.md) | [0.3 d](/filings/0001628280-25-038340.md) | [0.3 d](/filings/0001062822-25-000054.md) | [0.5 d](/filings/0001062822-26-000050.md) | not reported | not reported | [0.0 d](/filings/0001062822-25-000054.md) | [0.0 d](/filings/0001062822-26-000050.md) | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001062822-24-000060.md) | [0.0 d](/filings/0001062822-25-000013.md) | [1.7](/filings/0001062822-24-000024.md) | [0.0 d](/filings/0001062822-24-000046.md) | [0.0 d](/filings/0001062822-24-000060.md) | [0.0 d](/filings/0001062822-25-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [175](/filings/0001062822-23-000058.md) | [189](/filings/0001062822-24-000024.md) | [205](/filings/0001062822-24-000046.md) | [245](/filings/0001062822-24-000060.md) | [245](/filings/0001062822-25-000029.md) | [311](/filings/0001628280-25-038340.md) | [361](/filings/0001062822-25-000054.md) | [362](/filings/0001062822-26-000101.md) | [364](/filings/0001062822-26-000117.md) | [363](/filings/0001062822-25-000054.md) | [400](/filings/0001062822-26-000101.md) | [438](/filings/0001062822-26-000117.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 444,955,934 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001062822-26-000117.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.